PMID- 19196481
OWN - NLM
STAT- MEDLINE
DCOM- 20090505
LR  - 20211020
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 9
DP  - 2009 Feb 5
TI  - High resolution human leukocyte antigen (HLA) class I and class II allele typing 
      in Mexican mestizo women with sporadic breast cancer: case-control study.
PG  - 48
LID - 10.1186/1471-2407-9-48 [doi]
AB  - BACKGROUND: The development of breast cancer is multifactorial. Hormonal, 
      environmental factors and genetic predisposition, among others, could interact in 
      the presentation of breast carcinoma. Human leukocyte antigen (HLA) alleles play 
      an important role in immunity (cellular immunity) and may be important genetic 
      traits. HLAAllele-specific interaction has not been well established. Recently, 
      several studies had been conducted in order to do so, but the results are 
      controversial and in some instances contradictory. METHODS: We designed a 
      case-control study to quantify the association of HLA class I and II genes and 
      breast cancer. HLA typing was performed by high resolution sequence-specific 
      oligotyping after DNA amplification (PCR-SSOP) of 100 breast cancer Mexican 
      mestizo patients and 99 matched healthy controls. RESULTS: HLA-A frequencies that 
      we were able to observe that there was no difference between both groups from the 
      statistical viewpoint. HLA-B*1501 was found three times more common in the case 
      group (OR, 3.714; p = 0.031). HLA-Cw is not a marker neither for risk, nor 
      protection for the disease, because we did not find significant statistical 
      differences between the two groups. DRB1*1301, which is expressed in seven cases 
      and in only one control, observing an risk increase of up to seven times and 
      DRB1*1602, which behaves similarly in being present solely in the cases (OR, 
      16.701; 95% CI, 0.947 - 294.670). DQ*0301-allele expression, which is much more 
      common in the control group and could be protective for the presentation of the 
      disease (OR, 0.078; 95% CI, 0.027-0.223, p = 0.00001). CONCLUSION: Our results 
      reveal the role of the MHC genes in the pathophysiology of breast cancer, 
      suggesting that in the development of breast cancer exists a disorder of immune 
      regulation. The triggering factor seems to be restricted to certain ethnic groups 
      and certain geographical regions since the relevant MHC alleles are highly 
      diverse. This is the first study in Mexican population where high resolutions HLA 
      typing has been performed in order to try to establish an association with 
      malignancy.
FAU - Cantu de Leon, David
AU  - Cantu de Leon D
AD  - Department of Gynecologic Oncology, Instituto Nacional de Cancerologia de Mexico, 
      Mexico City, Mexico. dcantude@yahoo.com
FAU - Perez-Montiel, Delia
AU  - Perez-Montiel D
FAU - Villavicencio, Veronica
AU  - Villavicencio V
FAU - Garcia Carranca, Alejandro
AU  - Garcia Carranca A
FAU - Mohar Betancourt, Alejandro
AU  - Mohar Betancourt A
FAU - Acuna-Alonzo, Victor
AU  - Acuna-Alonzo V
FAU - Lopez-Tello, Alberto
AU  - Lopez-Tello A
FAU - Vargas-Alarcon, Gilberto
AU  - Vargas-Alarcon G
FAU - Barquera, Rodrigo
AU  - Barquera R
FAU - Yu, Neng
AU  - Yu N
FAU - Yunis, Edmond J
AU  - Yunis EJ
FAU - Granados, Julio
AU  - Granados J
LA  - eng
PT  - Journal Article
DEP - 20090205
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Breast Neoplasms/*genetics/*immunology
MH  - Case-Control Studies
MH  - Female
MH  - Haplotypes
MH  - Histocompatibility Antigens Class I/*genetics/immunology
MH  - Histocompatibility Antigens Class II/*genetics/immunology
MH  - Humans
MH  - Middle Aged
PMC - PMC2653544
EDAT- 2009/02/07 09:00
MHDA- 2009/05/06 09:00
PMCR- 2009/02/05
CRDT- 2009/02/07 09:00
PHST- 2008/10/07 00:00 [received]
PHST- 2009/02/05 00:00 [accepted]
PHST- 2009/02/07 09:00 [entrez]
PHST- 2009/02/07 09:00 [pubmed]
PHST- 2009/05/06 09:00 [medline]
PHST- 2009/02/05 00:00 [pmc-release]
AID - 1471-2407-9-48 [pii]
AID - 10.1186/1471-2407-9-48 [doi]
PST - epublish
SO  - BMC Cancer. 2009 Feb 5;9:48. doi: 10.1186/1471-2407-9-48.